Bioequivalence Study of Letrozole 2.5 mg Tablets
N/A
Completed
NCT01084499
| Condition | Healthy |
|---|
| Phase | N/A |
|---|
| Sponsor | Yuhan Corporation |
|---|
| Status | Completed |
|---|
| Enrollment | 26 participants |
|---|
| Interventions | Femara (Sequence 1), Peratra (Sequence 1), Femara (Sequence 2), Peratra (Sequence 2) |
|---|
| Start date | Jan, 2009 |
|---|
| Completion date | Apr, 2009 |
|---|
| Results posted | Mar 29, 2019 |
|---|
Summary
Bioequivalence
Letrozole : AUC0-tz
Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 96, 168, 312 hrs after drug administration · ng•hr/mL
| Peratra | 2074.71 ± 826.15 ng•hr/mL |
|---|
| Femara | 2094.63 ± 870.79 ng•hr/mL |
|---|
Letrozole : Cmax
Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 96, 168, 312 hrs after drug administration · ng/mL
| Peratra | 35.38 ± 6.66 ng/mL |
|---|
| Femara | 38.13 ± 7.03 ng/mL |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.